Tweedy Browne Co LLC Buys Shares of 2,696 Elevance Health, Inc. $ELV

Tweedy Browne Co LLC purchased a new position in shares of Elevance Health, Inc. (NYSE:ELV) during the 3rd quarter, Holdings Channel.com reports. The institutional investor purchased 2,696 shares of the company’s stock, valued at approximately $871,000.

Other hedge funds and other institutional investors have also modified their holdings of the company. Auxier Asset Management LLC grew its stake in Elevance Health by 0.9% in the 3rd quarter. Auxier Asset Management LLC now owns 37,096 shares of the company’s stock worth $11,986,000 after acquiring an additional 343 shares during the period. Captrust Financial Advisors lifted its stake in shares of Elevance Health by 0.3% during the 3rd quarter. Captrust Financial Advisors now owns 42,653 shares of the company’s stock worth $13,782,000 after purchasing an additional 117 shares during the period. Coldstream Capital Management Inc. grew its position in shares of Elevance Health by 8.5% in the third quarter. Coldstream Capital Management Inc. now owns 5,974 shares of the company’s stock valued at $1,930,000 after purchasing an additional 467 shares during the period. Aspire Private Capital LLC increased its stake in Elevance Health by 10.9% in the third quarter. Aspire Private Capital LLC now owns 1,128 shares of the company’s stock valued at $365,000 after purchasing an additional 111 shares during the last quarter. Finally, Danica Pension Livsforsikringsaktieselskab purchased a new position in Elevance Health during the third quarter worth about $140,411,000. 89.24% of the stock is currently owned by hedge funds and other institutional investors.

Elevance Health Stock Performance

Elevance Health stock opened at $296.14 on Wednesday. The company has a market cap of $65.36 billion, a price-to-earnings ratio of 11.79, a price-to-earnings-growth ratio of 1.60 and a beta of 0.51. Elevance Health, Inc. has a 12 month low of $273.71 and a 12 month high of $458.75. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.54 and a quick ratio of 1.54. The stock’s 50-day moving average is $335.31 and its 200-day moving average is $334.16.

Elevance Health (NYSE:ELV) last issued its earnings results on Wednesday, January 28th. The company reported $3.33 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.10 by $0.23. The business had revenue of $49.31 billion during the quarter, compared to analysts’ expectations of $49.52 billion. Elevance Health had a return on equity of 15.59% and a net margin of 2.84%.The company’s revenue for the quarter was up 9.6% on a year-over-year basis. During the same quarter in the previous year, the business earned $3.84 EPS. Elevance Health has set its FY 2026 guidance at 25.500- EPS. Equities analysts anticipate that Elevance Health, Inc. will post 33.96 earnings per share for the current year.

Elevance Health Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, March 25th. Shareholders of record on Tuesday, March 10th will be paid a dividend of $1.72 per share. This is an increase from Elevance Health’s previous quarterly dividend of $1.71. This represents a $6.88 annualized dividend and a yield of 2.3%. The ex-dividend date is Tuesday, March 10th. Elevance Health’s payout ratio is presently 27.39%.

Wall Street Analyst Weigh In

ELV has been the subject of several recent analyst reports. Wall Street Zen cut Elevance Health from a “buy” rating to a “hold” rating in a report on Sunday, February 8th. Jefferies Financial Group cut their price objective on shares of Elevance Health from $401.00 to $395.00 and set a “buy” rating on the stock in a report on Friday, January 30th. Robert W. Baird boosted their target price on shares of Elevance Health from $297.00 to $340.00 and gave the company a “neutral” rating in a report on Thursday, December 11th. Truist Financial dropped their price target on shares of Elevance Health from $400.00 to $390.00 and set a “buy” rating for the company in a research report on Monday, February 2nd. Finally, Mizuho cut their price target on shares of Elevance Health from $413.00 to $350.00 and set an “outperform” rating on the stock in a research note on Wednesday, March 11th. Twelve investment analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $387.40.

Elevance Health Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.